<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249414</url>
  </required_header>
  <id_info>
    <org_study_id>PV500PERF</org_study_id>
    <nct_id>NCT04249414</nct_id>
  </id_info>
  <brief_title>Post-hoc Analysis of Regional Pulmonary Perfusion and Hemodynamic Parameters Measured by Electrical Impedance Tomography</brief_title>
  <official_title>Post-hoc Analysis of Regional Pulmonary Perfusion and Hemodynamic Parameters Measured by Electrical Impedance Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drägerwerk AG &amp; Co. KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prof. Dr. med. Imhoff</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Drägerwerk AG &amp; Co. KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Define the capability and reliability of the PulmoVista® 500 (PV500) to detect changes in
      global and regional ventilation and perfusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The results of this study will help defining the capability and reliability of PulmoVista®
      500 (PV500) to detect changes in both global and regional ventilation and perfusion. As this
      is a non-invasive, observational trial, neither a positive nor a negative impact on the
      actual study participants is expected. The results will, however, improve the knowledge about
      the electrical impedance tomography (EIT) technology and thus aid the use of this technology
      for the benefit of future patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess regional distribution of pulmonary perfusion</measure>
    <time_frame>within 24 hours</time_frame>
    <description>The capability of PulmoVista® 500 for assessing regional distribution of pulmonary perfusion based on pulsatility signals and based on indicator dilution and changes at different points in time during varying states of regional ventilation will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess hemodynamic parameter cardiac output</measure>
    <time_frame>within 24 hours</time_frame>
    <description>The capability of PulmoVista® 500 for assessing cardiac output (relative values compared to reference given in l/min) will be explored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess hemodynamic parameter heart rate</measure>
    <time_frame>within 24 hours</time_frame>
    <description>The capability of PulmoVista® 500 for assessing heart rate (1/min) will be explored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess hemodynamic parameter stroke volume variability</measure>
    <time_frame>within 24 hours</time_frame>
    <description>The capability of PulmoVista® 500 for assessing stroke volume variability (relative value in % for 30 seconds compared to reference given in ml) will be explored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess oxygenation status</measure>
    <time_frame>within 24 hours</time_frame>
    <description>The capability PulmoVista® 500 for assessing the oxygenation status from both the regional distribution of alveolar ventilation and the regional distribution of pulmonary perfusion will be explored.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Mechanical Ventilation</condition>
  <condition>Ventilation Perfusion Mismatch</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PulmoVista 500</intervention_name>
    <description>Monitoring of Ventilation and Perfusion with the PulmoVista 500 during clinical routine.
No medical interventions required</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in the ICU who are mandatorily ventilated for at least 48 hours.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 80 years

          -  Mandatorily ventilated intensive-care patients with impairment in oxygenation (P/F
             ratio &lt; 300 at PEEP ≥ 5) ventilated at a positive end-expiratory pressure (PEEP) not
             exceeding 10 mbar and an fraction of inspired oxygen (FiO2) chosen, such that pulse
             oximetry is sensitive towards arterial oxygen pressure (PaO2) changes.

          -  Expected ventilation time &gt;48h

          -  Existing central venous and arterial access

          -  Chest circumference 70 - 150 cm

          -  Mandatory mechanical ventilation (patients without spontaneous efforts)

          -  Serum levels of sodium and chloride within normal range

          -  Cardiac output monitoring in place (PICCO)

        Exclusion Criteria:

          -  Contraindication to central venous injection of 5 % sodium chloride (NaCl) (e.g.
             elevated Na+ and/or Cl- concentration: Na+ should not exceed 150 mmol/l, Chloride
             should not exceed 115 mmol/l, known hypernatremia, known high serum osmolality)

          -  Contraindications of PulmoVista 500:

               -  Patients with pacemakers, defibrillators or other electrically active implants

               -  Patients with damaged skin or impaired skin contact of the electrodes due to
                  wound dressings

               -  Patients where the attachment of the patient belt could pose a risk to the
                  patient, e.g. patients with spinal lesions or fractures

               -  Patients with uncontrolled body movements

               -  Extremely obese patients (BMI&gt;50)

               -  Patients during pregnancy

               -  Patients with massive lung edema

               -  Use during electricity-based therapies, such as electrosurgery or electrocautery

               -  Use in the presence of strong magnetic fields

               -  Use in conjunction with other bioimpedance measurement devices

          -  Infection or colonization with multi-resistant pathogens that require isolation of the
             patient (e.g. MRSA)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Onnen Mörer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre of Anaesthesiology University Medical Center Göttingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Quintel, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Centre of Anaesthesiology University Medical Center Göttingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Birgit Stender</last_name>
    <phone>+49451882</phone>
    <phone_ext>6448</phone_ext>
    <email>birgit.stender@draeger.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulla Schöning, M.Sc.</last_name>
    <phone>+49451882</phone>
    <phone_ext>5612</phone_ext>
    <email>ClinicalAffairs@draeger.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Onnen Mörer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventilation Monitoring</keyword>
  <keyword>Electrical Impedance Tomography</keyword>
  <keyword>Perfusion Monitoring</keyword>
  <keyword>Hemodynamic Monitoring</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

